Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study on ovarian function protection with GnRH analogues during chemotherapy for gynecologic malignancies
2007-005475-34Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Leugon in Cervical Cancer (CC), breast cancer, ovarian cancer and 2 more, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Intact ovarian function at 1 year after completion of oncologic therapy and Tolerability and adverse effects of GnRH analogue therapy. Started Mar 2008; status: completed.
02
Drugs
Leugon
03
Conditions
Cervical Cancer (CC)breast cancerovarian cancervaginal cancerVulval carcinoma
Beyond the preview
Go deeper on 2007-005475-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005475-34.